JP2013522168A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522168A5 JP2013522168A5 JP2012554034A JP2012554034A JP2013522168A5 JP 2013522168 A5 JP2013522168 A5 JP 2013522168A5 JP 2012554034 A JP2012554034 A JP 2012554034A JP 2012554034 A JP2012554034 A JP 2012554034A JP 2013522168 A5 JP2013522168 A5 JP 2013522168A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- seq
- cargo molecule
- fusion protein
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33837710P | 2010-02-17 | 2010-02-17 | |
| US61/338,377 | 2010-02-17 | ||
| PCT/US2011/025312 WO2011103339A1 (en) | 2010-02-17 | 2011-02-17 | Use of pten-long leader sequence for transmembrane delivery of molecules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013522168A JP2013522168A (ja) | 2013-06-13 |
| JP2013522168A5 true JP2013522168A5 (https=) | 2014-05-08 |
| JP6009360B2 JP6009360B2 (ja) | 2016-10-19 |
Family
ID=44483307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012554034A Expired - Fee Related JP6009360B2 (ja) | 2010-02-17 | 2011-02-17 | 分子の膜通過送達のためのｐｔｅｎロングリーダー配列の使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9074011B2 (https=) |
| EP (1) | EP2536420A4 (https=) |
| JP (1) | JP6009360B2 (https=) |
| CN (1) | CN102844043B (https=) |
| AU (1) | AU2011218037B2 (https=) |
| BR (1) | BR112012020556A8 (https=) |
| CA (4) | CA3017717A1 (https=) |
| MX (1) | MX2012009565A (https=) |
| WO (1) | WO2011103339A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010216370A1 (en) | 2009-02-17 | 2011-09-22 | The Trustees Of Columbia University In The City Of New York | Identification of extracellular form of PTEN that can be used to treat tumors |
| WO2011103389A1 (en) | 2010-02-19 | 2011-08-25 | Cornell University | Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases |
| EP3365026B1 (en) * | 2015-10-19 | 2021-09-22 | University of Massachusetts | Anti-cancer and anti-inflammatory therapeutics and methods thereof |
| SG11201900815UA (en) * | 2016-07-29 | 2019-02-27 | Ohio State Innovation Foundation | Expression of pten-long with ocolytic viruses |
| CN109022462B (zh) | 2017-06-08 | 2021-12-21 | 中山大学附属第一医院 | 一种PTEN基因的上游开放阅读框31aa-uORF核苷酸及其编码的多肽的应用 |
| CN108504671A (zh) * | 2018-03-28 | 2018-09-07 | 宁波市医疗中心李惠利医院 | 一种PTEN-Long蛋白纯化制备方法 |
| CN108484780A (zh) * | 2018-04-16 | 2018-09-04 | 河南大学 | 一种融合蛋白PTEN-L-p53及其应用 |
| CN109224075B (zh) * | 2018-08-07 | 2021-11-16 | 浙江大学 | Pten抑制剂在制备治疗1型糖尿病药物中的应用 |
| CA3134665A1 (en) * | 2019-04-12 | 2020-10-15 | Therapten Biosciences Inc. | Compositions and methods to manufacture tumor suppressor fusions |
| CN112877309B (zh) * | 2021-02-19 | 2022-05-17 | 北京大学 | 一种N端延长型PTEN亚型PTENζ蛋白及其编码基因和应用 |
| CN113666998B (zh) * | 2021-08-10 | 2023-03-21 | 北京大学 | 一种具有调控神经系统发育功能的PTEN亚型蛋白PTENδ及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6482795B1 (en) * | 1997-01-30 | 2002-11-19 | Myriad Genetics, Inc. | Tumor suppressor designated TS10q23.3 |
| AU2010216370A1 (en) | 2009-02-17 | 2011-09-22 | The Trustees Of Columbia University In The City Of New York | Identification of extracellular form of PTEN that can be used to treat tumors |
-
2011
- 2011-02-17 CN CN201180018210.8A patent/CN102844043B/zh not_active Expired - Fee Related
- 2011-02-17 JP JP2012554034A patent/JP6009360B2/ja not_active Expired - Fee Related
- 2011-02-17 CA CA3017717A patent/CA3017717A1/en not_active Abandoned
- 2011-02-17 BR BR112012020556A patent/BR112012020556A8/pt not_active Application Discontinuation
- 2011-02-17 CA CA2790046A patent/CA2790046C/en not_active Expired - Fee Related
- 2011-02-17 WO PCT/US2011/025312 patent/WO2011103339A1/en not_active Ceased
- 2011-02-17 CA CA3017701A patent/CA3017701C/en not_active Expired - Fee Related
- 2011-02-17 CA CA3017689A patent/CA3017689A1/en not_active Abandoned
- 2011-02-17 MX MX2012009565A patent/MX2012009565A/es active IP Right Grant
- 2011-02-17 EP EP11745260.7A patent/EP2536420A4/en not_active Withdrawn
- 2011-02-17 US US13/579,025 patent/US9074011B2/en not_active Expired - Fee Related
- 2011-02-17 AU AU2011218037A patent/AU2011218037B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013522168A5 (https=) | ||
| Chen et al. | Targeted drug delivery to hepatic stellate cells for the treatment of liver fibrosis | |
| Stuckey et al. | TRAIL on trial: preclinical advances in cancer therapy | |
| Binder et al. | PASylation®: a versatile technology to extend drug delivery | |
| Ruoslahti | Peptides as targeting elements and tissue penetration devices for nanoparticles | |
| Kievit et al. | Surface engineering of iron oxide nanoparticles for targeted cancer therapy | |
| Zhang et al. | Oral delivery of biologics in inflammatory bowel disease treatment | |
| Paciotti et al. | Colloidal gold nanoparticles: a novel nanoparticle platform for developing multifunctional tumor‐targeted drug delivery vectors | |
| Iversen et al. | Optimized siRNA-PEG conjugates for extended blood circulation and reduced urine excretion in mice | |
| CN115521374B (zh) | 条件活性多肽 | |
| CN101610793B (zh) | 长效药物制剂 | |
| Saber et al. | Lipid nanoparticles for nucleic acid delivery beyond the liver | |
| Joo et al. | The potential and advances in RNAi therapy: Chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers | |
| Karim et al. | Therapeutic potency of nanoformulations of siRNAs and shRNAs in animal models of cancers | |
| CN102282259A (zh) | 与有义构建体实现期望多核苷酸的表达的用途相组合的、sirna实现内源基因的减量调节的用途 | |
| JP2010514779A5 (https=) | ||
| US20220143197A1 (en) | siRNA Inhibition Of Human Antigen R Expression For Treatment of Cancer | |
| CN111278847B (zh) | 分子导向系统肽及其用途 | |
| Zhang et al. | Strategies for developing long-lasting therapeutic nucleic acid aptamer targeting circulating protein: The present and the future | |
| Florian et al. | Gene engineered mesenchymal stem cells: greater transgene expression and efficacy with minicircle vs. plasmid DNA vectors in a mouse model of acute lung injury | |
| KR101223484B1 (ko) | 사람 혈청 알부민-ｓｉＲＮＡ 나노입자 전달체 | |
| Ning et al. | Gene reprogramming armed macrophage membrane-camouflaged nanoplatform enhances bionic targeted drug delivery to solid tumor for synergistic therapy | |
| US20170333571A1 (en) | Targeted Delivery Platform for Delivery of Therapeutics | |
| Winkler | Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides | |
| Xia et al. | Tissue-specific delivery of oligonucleotides |